Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill combo could replace chemo before ovarian cancer surgery

NCT ID NCT07033819

First seen Mar 03, 2026 · Last updated May 20, 2026 · Updated 17 times

Summary

This study tests two oral drugs, fuzuloparib and apatinib, given before surgery for people with advanced ovarian cancer that has a specific genetic marker (HRD-positive). The goal is to shrink tumors enough for complete removal and avoid chemotherapy. About 48 participants will receive the drug combo for several weeks before surgery. The study aims to see if this approach improves surgery success and long-term survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    RECRUITING

    Beijing, Beijing Municipality, 100021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.